Search Results

Displaying Results 1-23 of 23 "'CLGN'"

May 29, 2026, 07:00 ET COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

REHOVOT, Israel, May 29, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and medical aesthetics company developing innovative technologies and products based on its non-animal-derived recombinant human collagen

More news about: CollPlant


Apr 13, 2026, 07:00 ET CollPlant Issues Letter to Shareholders

April 13, 2026 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary plant-derived recombinant human

More news about: CollPlant


Mar 26, 2026, 08:30 ET COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

REHOVOT, Israel, March 26, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived rhCollagen for tissue

More news about: CollPlant


Mar 24, 2026, 16:01 ET CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

REHOVOT, Israel, March 24, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen)

More news about: CollPlant


Mar 18, 2026, 09:00 ET CollPlant Biotechnologies Launches Redesigned Corporate Website

REHOVOT, Israel, March 18, 2026 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary plant-derived recombinant human

More news about: CollPlant


Mar 11, 2026, 08:00 ET COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS

March 11, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for medical

More news about: CollPlant


Feb 26, 2026, 08:00 ET CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler

Feb. 26, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary  recombinant human collagen

More news about: CollPlant


Feb 23, 2026, 07:00 ET CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex

ReproducibilityREHOVOT, Israel, Feb. 23, 2026 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen)

More news about: CollPlant


Feb 17, 2026, 07:00 ET CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments

Feb. 17, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen),

More news about: CollPlant


Feb 05, 2026, 08:00 ET COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING

REHOVOT, Israel, Feb. 5, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue

More news about: CollPlant


Nov 26, 2025, 07:30 ET COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

REHOVOT, Israel, Nov. 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue

More news about: CollPlant


Nov 18, 2025, 07:00 ET COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS

REHOVOT, Israel, Nov. 18, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue

More news about: CollPlant


Oct 27, 2025, 07:01 ET CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada

REHOVOT, Israel, Oct. 27, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen),

More news about: CollPlant


Oct 20, 2025, 07:00 ET CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology

REHOVOT, Israel, Oct. 20, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen),

More news about: CollPlant


Oct 16, 2025, 07:00 ET First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk

REHOVOT, Israel, Oct. 16, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its proprietary, non-animal recombinant human

More news about: CollPlant


Sep 30, 2025, 07:00 ET CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler

REHOVOT, Israel, Sept. 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its proprietary non-animal recombinant human

More news about: CollPlant


Sep 15, 2025, 07:00 ET CollPlant Expands the Distribution of its VergenixSTR Product in Europe

Israel, Sept. 15, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or 'CollPlant', a regenerative and aesthetics medicine company developing innovative

More news about: CollPlant


Sep 02, 2025, 07:00 ET CollPlant to Present at the 2025 International Conference on Biofabrication

Israel, Sept. 2, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen

More news about: CollPlant


Aug 25, 2025, 07:00 ET CollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Israel, Aug. 25, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen

More news about: CollPlant


Aug 20, 2025, 07:00 ET COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Israel, Aug. 20, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue

More news about: CollPlant


Aug 05, 2025, 07:00 ET COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS

Aug. 5, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue

More news about: CollPlant


Jul 14, 2025, 07:00 ET CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations

Israel, July 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen

More news about: CollPlant


Jun 09, 2025, 07:00 ET COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES

Israel, June 9, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-derived, Type I recombinant human

More news about: CollPlant


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.